According to a market report by Lucintel, the future of the global live attenuated vaccine market looks promising with opportunities in the hospital, clinic, diagnostics center, and research institute markets. The global live attenuated vaccine market is expected to reach an estimated $9.8 billion by 2030 with a CAGR of 9.5% from 2024 to 2030. The major drivers for this market are cumulating need for more effective vaccines, expanding awareness of the benefits of vaccination, and supportive government initiatives to promote vaccination programs.

In this market, bacterial and viral are the two major segments of live attenuated vaccine market by type.
Lucintel forecasts that viral is expected to witness higher growth over the forecast period due to its significant usage for the effective prevention of viral infections.
Within this market, hospital is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to the existence of well developed healthcare infrastructure and presence of supported government vaccination campaigns among individuals in the region.

Glaxosmithekline, Merck & Co, Medimmune, Sanofi, Serum Institute India, Emergent Biosolutions, and CSL are the major suppliers in the live attenuated vaccine market. "
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]